Verition Fund Management
ENTA icon

Verition Fund Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Verition Fund Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-39,069
Closed -$436K – 2426
2023
Q3 		$436K Buy
39,069
+29,113
+292% +$469K 0.01% 1522
2023
Q2 		$213K Buy
+9,956
New +$294K ﹤0.01% 1808
2019
Q3 		– Sell
-2,718
Closed -$229K – 1121
2019
Q2 		$229K Buy
+2,718
New +$244K 0.01% 937

Other funds holding ENTA

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Verition Fund Management's ENTA Position: Q4 2023 in Review

Verition Fund Management sold out of Enanta Pharmaceuticals (ENTA) in Q4 2023, closing a stake of 39,069 shares — an estimated $436K sold.

Verition Fund Management first reported a position in ENTA in Q2 2019 and held it in 3 quarters. The position peaked at $436K in Q3 2023. 105 funds tracked by Wall St. Rank hold ENTA as of Q4 2023.

  • Verition Fund Management reported no remaining Enanta Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Verition Fund Management sold 39,069 Enanta Pharmaceuticals shares in Q4 2023, an estimated $436K.
  • Verition Fund Management first reported a position in Enanta Pharmaceuticals in Q2 2019 and held it in 3 quarters.
  • Verition Fund Management's Enanta Pharmaceuticals position peaked at $436K in Q3 2023.
  • 105 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2023.

Based on Verition Fund Management's 13F filing for Q4 2023, filed 14 Feb 2024.